Ankura Consulting Group, LLC | USA | 20 Oct 2023
In the Gulf Cooperation Council (GCC) region, mid-market capitalization investors have a unique opportunity to acquire or establish Shared Service…
Bergeson & Campbell PC | USA | 1 Mar 2023
The Senate Committee on Environment and Public Works held a hearing on February 15, 2023, on “The Future of…
Audio
McDermott Will & Emery | USA | 10 Nov 2022
The Board’s executive compensation committee is the focus point for many of the extraordinary financial, economic and operating challenges currently…
Lexology PRO | Australia, Canada, European Union, etc. | 8 Nov 2022
Tim Parilla, Chief Legal Officer at LinkSquares, shares tips on how GCs at small companies can build relationships, utilise outside counsel and make a case for expanding the legal team where budgets can be tight.
Stephenson Harwood LLP | Asia-Pacific, Singapore | 3 Nov 2022
In Singapore new corporate disclosures have come into force: requirements for companies (including some foreign companies) to maintain a register of…
Cooley LLP | USA | 8 Jun 2022
Are corporate boards awash in faux gatekeepers? This article, Board Gatekeepers, from a law professor at the University of Wisconsin, begins with a…
BCLP | Hong Kong | 6 Jan 2022
On 12 October 2021, the Competition Tribunal (“Tribunal”) handed down its judgment on the merits of the first private action in Hong Kong for a…
Association of Corporate Counsel | Global, USA | 22 Oct 2021
ACC, in partnership with Exterro, the exclusive ACC Alliance Partner for eDiscovery, data privacy, and cybersecurity, presents the results of the…
Lexology PRO | Central & South America, European Union, France, etc. | 9 Aug 2021
The UK’s antitrust watchdog has agreed to advise the government on whether travellers are being charged excessive prices for covid-19 tests after the health secretary asked it to conduct a “rapid high-level review”.
Lexology PRO | European Union, United Kingdom | 5 Aug 2021
The UK’s Competition and Markets Authority has accused Pfizer and Flynn Pharma of charging unfairly high prices for an anti-epilepsy medication, 17 months after an appellate court ordered the agency to redo parts of its initial probe into the drugmakers.